Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Trial Profile

A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs Selinexor (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Acronyms ESSENTIAL
  • Most Recent Events

    • 15 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.
    • 20 Sep 2018 Planned number of patients changed from 18 to 56.
    • 20 Sep 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top